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Abstract 
Background: Laparoscopic sleeve gastrectomy (LSG) is an effective treatment for obesity 
and associated metabolic complications. Obesity and type 2 diabetes are associated with 
increased oxidative stress. Previous studies have examined changes in plasma oxidative 
stress following Roux-en-Y Gastric Bypass, but there is limited evidence of the effects of LSG. 
Objectives: To examine the effects of LSG on plasma thiobarbituric acid reactive substances 
(TBARS) and total antioxidant status (TAOS) at 1 and 6 months following LSG in subjects with 
obesity and impaired glucose regulation.  
Setting: University Hospital, United Kingdom. 
Methods: Twenty-two participants with impaired glucose homeostasis undergoing LSG 
(body mass index [BMI] 50.1kg/m2, glycated haemoglobin [HbA1c] 53mmol/mol) were 
studied. Measurements of fasting and 120 minute TBARS and TAOS were performed during 
an oral glucose tolerance test pre-operatively and post-operatively.  
Results: Compared to pre-operative levels, significant decreases were seen 6 months post-
operatively in fasting TBARS (61.0±17.9 v 39.4±13.8ng/mL, p=0.04) and 120 minute TBARS 
(76.0±29.5 v 46.5±16.3ng/mL, p=0.02). No significant changes were observed in plasma 
TAOS. No significant association was observed between changes in TBARS and other clinical 
or biochemical measures. 
Conclusion: We observed a significant reduction in TBARS, a global measure of lipid 
peroxidation 6 months following LSG in participants with obesity and impaired glucose 
regulation.  
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Introduction 
Obesity and related impaired glucose homeostasis are associated with increased circulating 
and tissue levels of reactive oxygen species (ROS) (1, 2) and oxidative damage. ROS are 
associated with systemic inflammation, vascular and endothelial dysfunction (3), β-cell 
dysfunction (4-6), insulin resistance, type 2 diabetes and associated complications (7, 8). 
Bariatric surgery is an effective treatment for obesity and obesity-associated impaired 
glucose homeostasis (impaired glucose tolerance and type 2 diabetes) (9). This is likely to 
occur through a reduction in adipose tissue mass and subsequent improvements in systemic 
inflammation (10, 11) and oxidative stress (12, 13). Previous publications have demonstrated 
reductions in systemic measures of inflammation following laparoscopic Roux-en-Y Gastric 
Bypass (RYGB) (14-17) and laparoscopic sleeve gastrectomy (LSG) (17-20). LSG is an established 
and recognized stand-alone bariatric procedure and has an established safety profile 
comparable to other bariatric procedures (21, 22). There are few published studies examining 
changes in plasma markers of oxidative stress following bariatric surgery, especially LSG. In 
relation to RYGB, Ueda et al (23), observed reductions in plasma levels of F2-isoprostane (8-
iso-PGF2α) and an increase in glutathione peroxidise (GPX) in 14 subjects within the first 
week of surgery. These changes were also associated with changes in adipocyte levels of 8-
iso-PGF2α and an increase in the adipocyte expression of GPX-3. Carbrear et al (24), reported 
significant reductions in plasma superoxide dismutase (SOD) and malondialdehyde (MDA) 
and increases in glutathione and total reactive antioxidant potential (TRAP) in 20 subjects 
twelve months after surgery. Two other studies have shown that weight reduction per se 
was associated with improvements in plasma measures of oxidative stress following RYGB 
(12, 13). Kelly and colleagues (17) reported significant improvements in markers of both 
inflammation and oxidative stress, but this was in a combined cohort of both RYGB and 
4 
 
vertical sleeve gastrectomy. Our aim was to specifically examine the temporal changes in 
fasting and 120 minute plasma TBARS and TAOS following a glucose load (an oral glucose 
tolerance test) pre-operatively and at 1 and 6 months following LSG in a sample of subjects 
with impaired glucose tolerance or type 2 diabetes. These measures provide a global plasma 
measure of oxidative stress (TAOS) and a specific measure of lipid peroxidation (TBARS).  
 
Methods 
Study participants 
Approval for the study was obtained from the Local Research Ethics Committee and the 
Joint Scientific Research Committee. Participants were identified and recruited from 
patients undergoing a planned bariatric surgical procedure at our centre. Entry criteria at 
the outset of the study included:- both sexes, age 20-60 years, BMI >40kg/m2 and physically 
fit for surgery. Participants with any acute concurrent illness were excluded. Participants 
with pre-existing type 2 diabetes treated with diet, oral agents or insulin were included. 
Participants with impaired glucose regulation were those with either impaired fasting 
glycaemia (5.6-6.9 mmol/L) or impaired glucose tolerance (2-hour glucose 7.8-11.0 mmol/L) 
(25). Participants with normal fasting glucose values or a normal glucose tolerance test prior 
to recruitment were excluded. At the time of recruitment no participant was known to be 
taking any form of vitamin supplementation, and no vitamin supplementations are given 
routinely following LSG. No participant had any diagnosed or clinically manifest systemic 
immune or inflammatory disorder. Informed consent was obtained from all individual 
participants included in the study. 
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Study design 
Participants with a planned LSG were recruited prospectively and consecutively from the 
bariatric surgical clinic. The LSG was a standard sleeve (sleeve fashioned around a 32F 
bougie taken from 5cm proximal to the pylorus and up to the left crus). All participants were 
recruited pre-operatively (within 1 month of surgery) and followed up post-operatively at 1 
and 6 months. Baseline questionnaire and all clinical measurements were documented 
during visits. All blood samples were collected after stopping any prescribed insulin or oral 
hypoglycaemic agent for 24 hours prior to an oral glucose tolerance test (OGTT) performed 
with 75g of glucose (122ml of Polycal 61.9g/100ml of glucose, Nutricia Clinical Care, 
Trowbridge, UK). Previous studies have demonstrated that the level of glycaemia reached 2 
hours after 75g of glucose is closely related to the level of glycaemia after a standardised 
meal indicating an OGTT is a valid tool for revealing altered carbohydrate metabolism during 
a meal (26). There was no standardised meal prescribed for the night before and subjects 
were asked to fast from midnight before the test with diabetes related medication omitted.  
 
Baseline clinical and biochemical information 
At the time of screening the following clinical information was ascertained: age, gender, 
past medical history, treatment and duration of diabetes. Baseline clinical measurements 
consisted of weight, height, body mass index (BMI), waist circumference, systolic and 
diastolic blood pressure. Baseline biochemical measurements (total cholesterol, low density 
lipoprotein-cholesterol [LDL-C], high density lipoprotein-cholesterol [HDL-C] and 
triglycerides) were analysed within the local hospital accredited laboratory. Glucose and 
lipids (Roche Modular P800 Analyzer), and insulin and C-peptide (Roche E170 Modular 
Analyzer) were also measured locally. Total glucagon-like peptide-1 (GLP-1) was 
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quantitatively measured using the Total GLP-1 ELISA Kit (Epitope Diagnostics Inc,) which 
utilizes the two-site sandwich technique with two selected GLP-1 antibodies in order to 
assess both the intact GLP-1 amide (7-36) and the primary (NH2-terminally truncated) 
metabolite GLP-1 amide (9-36). The intra- and inter-assay coefficients of variation were 
4.7% and 9.5% respectively. 
 
All blood samples were centrifuged and separated within one hour of collection and 
subsequently stored at -80oC until analysis. Fasting EDTA samples were collected for the 
measurement of TAOS and TBARS immediately prior to the glucose load and 120 minutes 
afterwards. These were collected pre-operatively, and 1 and 6 months post-operatively. 
Glucose, C-peptide and GLP-1 were measured during each OGTT at time 0, 15, 30, 45, 60 
and 120 minutes. This allowed area under the curve analysis at 120 minutes (AUC120) to be 
calculated and examined in relation to changes in TBARS and TAOS. 
 
Measurement of lipid peroxidation (TBARS) 
MDA concentration, as a product of lipid peroxidation, was measured using a commercially 
available TBARS Assay (thiobarbituric acid reactive substances assay) (Caymen Chemical, MI, 
USA). Using a MDA standard curve, concentrations in plasma samples were calculated. A 
higher concentration of MDA is indicative of higher levels of lipid peroxidation, and 
therefore, higher oxidative stress within the sample. Intra- and inter-assay variability 
coefficients were 5.2% and 16.2% respectively. All samples were assayed in duplicate (27, 28). 
 
 
 
7 
 
Measurement of plasma total anti-oxidant status (TAOS) 
Plasma total anti-oxidant status (TAOS), which is inversely related to oxidative stress, was 
measured by Sampson’s modification of Laight’s photometric microassay (29). Previously, we 
have shown that plasma TAOS has a good correlation with plasma F2-isoprostanes 
(30, 31). The 
TAOS of plasma was determined by its capacity to inhibit the peroxidase-mediated 
formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid (ABTS+) radical. The 
difference in absorbance (control [saline] minus test [plasma]) divided by the control 
absorbance (expressed as a percentage) was used to represent the percentage inhibition of 
the reaction. Intra- and inter-assay variability coefficients were 4.3% and 10.1% respectively. 
All samples were assayed in duplicate.  
 
Statistical methods 
Statistical analysis was performed using SPSS (version 20, SPSS Inc., Chicago). Results for 
continuous variables are presented as mean and standard deviation and in graphical 
representation as mean (TAOS) or geometric mean (TBARS) and standard error. Continuous 
variables that did not have a normal distribution (triglyceride and TBARS) underwent log 
transformation to normalize the data for analysis and are described with the geometric 
mean and approximate standard deviation. For continuous variables, temporal changes 
were compared between baseline and 1 or 6 months using a paired t-test. Categorical data 
were analysed using a Chi-squared test. Changes in the AUC120 were analysed during the 
OGTT pre-operatively and 1 and 6 months for glucose, C-peptide and GLP-1 using the 
trapezoidal rule. Correlations between temporal variables and changes in variables (delta 
values) were examined by Pearson’s correlation of continuous variables following log 
transformation if appropriate. In all cases a p<0.05 was considered statistically significant. 
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The study was explorative in nature and the sample size was dependent on the prospective 
recruitment of subjects with samples available for the plasma measure of oxidative stress. 
As described in the introduction, Carbrear et al (24), reported significant increases in total 
reactive antioxidant potential (TRAP) in 20 subjects twelve months after RYGB surgery, but 
there are no studies examining this in relation to LSG. Therefore, there are no previous 
studies to base a power calculation on the primary outcome of this study. With respect to 
changes in plasma markers of oxidative stress, we have previously observed a significant 
reduction in plasma TAOS (37%) within 8 hours following vaccination with typhoid vaccine 
(32) in a sample of 21 healthy volunteers. All measurements were significantly increased at 
this time point compared to baseline.   
 
Results 
Subject characteristics 
A total of 22 participants (7 males/15 females) who underwent a LSG (mean age 48±7 years) 
with impaired glucose homeostasis (50%) or type 2 diabetes (50%) (median duration of 42 
month [interquartile range 21-66 months]) were recruited. Of those with type 2 diabetes, 
27% were diet controlled, 46% taking oral hypoglycaemic agents and 27% were using 
insulin. Table 1 show the temporal changes between pre-operative, 1 and 6 months within 
the group. As seen in table 1, significant reductions were observed in weight, BMI and waist 
circumference at both 1 and 6 months post-operatively. We also observed a significant 
reduction in systolic blood pressure at 1 month but no significant changes in total 
cholesterol, LDL-C or triglyceride concentrations. Significant changes were observed in 
fasting glucose, 120 minute glucose, HbA1c, and AUC120 for glucose, C-peptide and GLP-1. 
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Additionally, 32% and 64% of patients had remission of their diabetes at 1 month and 6 
months post-LSG, respectively. 
 
Temporal changes in plasma markers of oxidative stress following LSG 
The mean temporal changes in fasting and 120 minute TBARS and TAOS between pre-
operative, 1 and 6 months are shown in Table 2. With respect to fasting plasma TBARS, 
there was a linear decrease in TBARS from the pre-operative period to 6 months post-
operatively. At 6 months the fasting TBARS had decreased by approximately 35% (p=0.04). 
Similarly, with respect to the 120 minute TBARS, there was a linear decrease with the levels 
at 6 months being approximately 40% lower than pre-operative levels (p=0.02). For TAOS, 
no significant increases were observed in fasting or the 120 minute levels at 6 months. 
 
Correlations of changes in TBARS with other metabolic parameters 
Correlations between TBARS, TAOS and the clinical and biochemical variables listed in table 
1 at the temporal time points were examined to determine whether changes in TBARS were 
related to changes in the other clinical and biochemical parameters following surgery. In 
addition the correlations between the changes (delta values) in TBARS and TAOS with 
changes (delta values) in the variables listed in table 1 were also examined. There was a 
positive correlation between fasting TBARS and 120 minute TBARS (r=0.58, p=0.01) pre-
operatively and 6 months post-operatively (r=0.58, p=0.02). No other temporal (pre-
operative, 1 or 6 months) correlations were observed between TBARS and any other clinical 
or biochemical measurement. Furthermore, no correlations between the changes (delta 
values) in TBARS or TAOS and changes (delta values) in the variables listed in table 1 were 
observed. 
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Discussion 
We observed that LSG was associated with a reduction in fasting and 120 minute glucose-
stimulated TBARS. TBARS is an easily measured global plasma marker of lipid peroxidation, a 
process dependent on oxidative stress and damage. Bariatric surgery in addition to reducing 
weight effectively reduces morbidity and mortality in obese individuals with favourable 
effects on vascular and endothelial dysfunction (3), β-cell dysfunction (4-6), insulin resistance, 
type 2 diabetes and associated complications (7, 8). These effects are clearly related to 
significant reductions in fat mass following surgery, but improvements in circulating levels of 
oxidative stress and inflammation are also likely to play an important role. We observed a 
linear decrease in TBARS at 1 and 6 months following LSG. To our knowledge this is the first 
manuscript that reports changes in a plasma marker of oxidative stress following this 
procedure that has gained recent popularity as an established operation (21, 22). Previously, 
with respect to RYGB, Ueda et al, observed reductions in plasma levels of 8-iso-PGF2α and 
an increase in GPX in 14 subjects within the first week of surgery (23). In line with this 
observation, Carbrear et al, reported significant reductions in plasma SOD and MDA levels 
and increases in glutathione and TRAP in 20 subjects twelve months after surgery (24). 
Furthermore, 2 other studies have shown that weight reduction per se is associated with 
improvements in plasma measures of oxidative stress following RYGB (12, 13). Therefore, our 
study is in keeping with those relating to RYGB surgery.  
 
Within this study we observed no changes in plasma fasting or postprandial TAOS, a 
measure of global plasma antioxidant status. Of note, within our study sample of morbidly 
obese participants with impaired glucose regulation, the mean and standard deviation of 
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plasma TAOS at each temporal point (Table 1) were relatively low compared to studies 
which have examined this marker previously (30). Part of this may be related to the fact that 
the study group still had significant risk factors associated with increased oxidative burden 
at 6 months and the antioxidant status may have been influenced by a dietary change post-
operatively. Two other published studies have observed no changes in plasma TAC in 
morbidly obese participants. Tinahones et al, in a sample of 60 subjects with a BMI of 
53.5±7.3kg/m2 observed no changes in TAC following a lipid rich meal but did observe 
changes in TBARS (33). Furthermore, Catoi et al, in a sample of 23 subjects with a BMI of 
48.4±8.4kg/m2 undergoing silastic ring vertical gastroplasty, observed no changes in total 
oxidant status and total antioxidant response 12 months following weight loss surgery (34). 
However, there were differences between the pre-operative measurements in morbidly 
obese patients compared to a control group (BMI 22.3±2.1kg/m2) at baseline. These 
observations suggest that measuring markers of global antioxidant status may not be the 
best measure of plasma oxidative stress in subjects with morbid obesity and where a 
relatively high BMI remains present. There has been considerable debate within the 
literature in relation to the biochemical measurement of plasma oxidative stress and the 
challenges these offer (3). Measuring plasma markers of oxidative stress is a challenge and 
options available include measuring global markers of oxidative damage such as total 
antioxidant status/capacity (TAOS/TAS/TAC), measuring products of lipid peroxidation such 
as thiobarbituric acid reactive substances (TBARS) or 8-iso-PGF2α, or measuring specific 
antioxidant molecules such as SOD or GPX. Further controversy exists on whether such 
measurements should be performed on a static fasting sample or following dynamic testing 
such as with a glucose load (29, 35, 36). By definition, ROS are highly reactive and are thus 
difficult to measure in any biological sample, especially in easily accessible specimens such 
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as serum or plasma, and therefore measuring plasma levels in the face of a pro-oxidant 
stimulus such as glucose may provide a better measure of the dynamic response within an 
ex-vivo sample (3). 
 
No correlations were observed between fasting and 120 minute TBARS and other measured 
clinical and biochemical parameters and furthermore no correlations were observed 
between changes (delta) in these variables. Therefore, the improvements seen in TBARS 
would appear to be independent of these factors. Of specific note, no association or 
correlation was observed with changes in glucose homeostasis, BMI or in AUC120 for glucose, 
C-peptide and GLP-1 in relation to the temporal OGTTs.  
 
It is well established that a close relationship exists between oxidative burden and low-
grade systemic inflammation and associated obesity, glucose dysregulation and endothelial 
dysfunction. We have previously described a reduction in systemic inflammation following 
LSG within this study sample in a previously published manuscript (20). We therefore 
examined to see if there were correlations between the previously measured inflammatory 
markers with TBARS in the current study. Pre-operatively no correlation was observed 
between fasting and 120 minute TBARS with interleukin-6, interleukin-10, C-reactive 
protein, adiponectin or leptin. Post-operatively, fasting TBARS had a significant correlation 
with adiponectin (r=-0.55, p=0.03) at 1 month and at 6 months this was borderline (r=-0.48, 
p=0.05). 
 
One limitation of the study was that the participant group comprised of those with impaired 
glucose tolerance and type 2 diabetes, however our aim was to examine changes in plasma 
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markers of oxidative stress in a sample of subjects with glucose dysregulation, which is itself 
associated with increased oxidative burden (3, 29). Furthermore, the median duration of 
diabetes was 42 months [interquartile range 21-66 months] and this might have an effect on 
levels of inflammatory markers pre-operatively. Other limitations of this observational study 
include the unbalanced gender distribution and small sample size. However the sample size 
is in line with previous studies relating to plasma markers of oxidative stress and RYGB 
surgery. Additionally, we do not have data regarding diet and/or exercise activity following 
surgery in these participants. Even though plasma F2-isoprostanes are seen as the gold 
standard measure of global oxidative stress we have previously demonstrated that plasma 
TAOS is a comparable methodology (30).  
 
Conclusion 
To our knowledge this is the first study to examine temporally at 1 and 6 months the effects 
of LSG on plasma markers of oxidative stress. This current study contributes to the available 
literature supporting the role of LSG for the treatment of impaired glucose regulation and 
pro-inflammatory conditions associated with morbid obesity. Further longer-term 
prospective studies are required to examine the effects of LSG (alone and versus other 
bariatric procedures such as RYGB) in relation to biomarkers of inflammation and oxidative 
stress in relation to the inflammatory mediated complications of obesity in participants with 
and without impaired glucose regulation. 
 
Conflict of interest:  The authors declare that there is no conflict of interest associated with 
this manuscript. 
Keywords: obesity; type 2 diabetes; sleeve gastrectomy; oxidative stress. 
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Table 1: Temporal changes in clinical and biochemical measures 
 
Measurement Baseline 1 month ap  6 months bp  
Weight (kg) 146.6 (29.6) 129.4 (26.9) <0.001 115.5 (24.4)  <0.001 
BMI (kg/m2) 50.1 (6.6) 44.0 (6.6) <0.001 39.6 (6.2) <0.001 
Waist (cm) 138 (18) 128 (17) <0.001 118 (18) <0.001 
Systolic BP (mmHg) 131 (18) 123 (14) 0.04 128 (20) 0.12 
Diastolic BP (mmHg) 76 (11) 74 (9) 0.63 73 (14) 0.13 
Cholesterol (mmol/L) 4.3 (1.0) 4.4 (1.1) 0.58 4.7 (1.2) 0.09 
LDL-C (mmol/L) 2.4 (0.8) 2.7 (1.0) 0.16 2.8 (0.9) 0.05 
HDL-C (mmol/L) 1.2 (0.3) 1.1 (0.3) 0.02 1.3 (0.3) 0.10 
Triglyceride (mmol/L)* 1.4 (0.4) 1.4 (0.2) 0.92 1.1 (0.2) 0.15 
HbA1c (%) 
HbA1c (mmol/mol) 
7.0 (1.7) 
53 (18.6) 
6.1 (0.8) 
43 (8.7) 
0.005 
0.005 
5.7 (0.8)  
39 (8.7) 
0.002 
   0.002 
Fasting glucose (mmol/L) 7.6 (3.6) 5.4 (0.9) 0.02 5.0 (1.0) 0.08 
120 minute glucose (mmol/L) 11.6 (5.9) 7.8 (3.4) 0.002 5.4 (2.2)  <0.001 
AUC120      
Glucose (mmol h L-1) 23.4 (7.3) 19.1 (3.5) 0.01 16.5 (4.7) 0.003 
C-peptide (pmol h L-1)* 16.9 (3.1) 21.5 (3.3) <0.001 17.7 (3.7) 0.04 
GLP-1 (pmol h L-1) 5.6 (5.1) 23.3 (10.9) <0.001 22.1 (12.6) <0.001 
BMI: body mass index; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein 
cholesterol; HBA1c: glycated hemoglobin; AUC120: area under the curve at 120 minutes; GLP-1: glucagon like 
peptide-1; BP: Blood pressure. Mean and standard deviation shown for continuous variables. 
*
log transformed 
for analysis with the geometric mean and approximate standard deviation shown. 
a
p-value comparing baseline 
with 1 month.
 b
p-value comparing baseline with 6 months 
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Table 2: Temporal changes in fasting and 120 minute TBARS and TAOS 
 
Measurement Baseline 1 month ap 6 months bp  
TBARS* (ng/mL)      
Fasting 70.0 (17.3) 49.7 (13.0) 0.14 39.4 (13.8) 0.04 
120 minutes 76.0 (29.5) 55.6 (14.3) 0.25 46.5 (16.3) 0.02 
TAOS (%)      
Fasting 43.1 (8.9) 37.3 (9.1) 0.03 40.9 (7.3) 0.25 
120 minutes 42.1 (8.2) 41.4 (7.3) 0.66 40.0 (11.2) 0.29 
TBARS: thiobarbituric acid reactive substances; TAOS: total antioxidant status. Mean and standard deviation 
shown for TAOS. 
*
log transformed for analysis. Geometric mean and approximate standard deviation shown for 
TBARS. 
a
p-value comparing baseline with 1 month.
 b
p-value comparing baseline with 6 months. 
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Figure 1: Temporal changes in inflammatory biomarkers following sleeve gastrectomy 
 
Figure 1a: TBARS 
Geometric mean and standard error shown for TBARS. Significant changes relative to 
baseline:*P=0.04, #P=0.02. See also Table 2. 
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Figure 1b: TAOS 
Mean and standard error shown for TAOS. 
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